Discovery,
in motion.
New mechanisms, new tools, and new recognition—follow the ideas shaping our program in spatial immunology and therapeutic cell engineering.
The work,
as it unfolds.
KLHL6 reveals a proteostasis checkpoint for CD8+ T-cell dysfunction
A convergent analysis across 136 datasets identifies a mechanism linking exhaustion resistance, mitochondrial fitness, and antitumor function.
Sequential transcriptional waves direct drug-induced cancer dedifferentiation
Temporal multi-omic analysis resolves how NF-κB-driven chromatin remodeling reshapes cell identity and drug response.
Yapeng Su named a Next Generation Leader
Recognition for emerging leadership at the intersection of systems immunology, quantitative biology, and therapeutic cell engineering.
A synthetic receptor converts TGF-β suppression into IL-2 survival signaling
The receptor recodes a hostile tumor cue to sustain engineered T-cell activation.
Mannose exposure installs a stem-like program in therapeutic T cells
Metabolic, transcriptional, and epigenetic profiling connects pre-infusion conditioning to durable antitumor function.
Pathway to independence and a STAT Wunderkind
An NIH/NCI K99–R00 award and STAT Wunderkind recognition accelerate an independent program in T-cell fate engineering.
Longitudinal systems immunology reveals early factors associated with long COVID
A multi-omic study connects acute-phase biology to later post-acute sequelae and sparks broad public discussion.
A systems view of immune responses to COVID-19
High-dimensional immune profiling links cell states, molecular programs, and clinical trajectories.
Science that
travels.
The long-COVID systems study reached audiences through national and international reporting—carrying multi-omic science beyond the scientific literature.

